Page 28 - Boletin SEHH Julio - Agosto 2018
P. 28
I SIMPOSIO “CÁNCER SIN BULOS”
Lugar: Auditorio del Hospital Clínico San Carlos
(Calle del Prof. Martín Lagos, s/n. 28040 Madrid)
Fecha: 19 de septiembre de 2018 Organiza: Salud sin bulos
Más información
I JORNADA AELEMIC “DÍA MUNDIAL
DE LA LEUCEMIA MIELOIDE CRÓNICA (LMC)”
–
APERTURA
I JORNADA DIA MUNDIAL AELEMIC LEUCEMIA MIELOIDE CRÓNICA
Lugar: Sala H004 del Hospital Universitario y Politécnico La Fe (Avinguda de Fernando Abril Martorell, 106.
46026 Valencia)
Fecha: 21 de septiembre de 2018
Organiza: Hospital Universitario y Politécnico La Fe
y Asociación Española de Enfermos de LMC (AELEMIC)
Inscripciones: [email protected] Programa
09:30 H.
[email protected]
Autoridades , Dirección Médica, Jefatura de Servicio de Hematología de LA FE,
Representante de SEHH y Presidente de AELEMIC.
09: 45 H. CHARLA INAUGURAL
“ LA LEUCEMIA MIELOIDE CRÓNICA UN PARADIGMA DE MEDICINA DE PRECISIÓN O PERSONALIZADA”
Dr. Miguel Ángel Sanz Alonso.- Director del Área de Gestión Clínica de Oncología y Hematología , Jefe del Servicio de Hematología y Trasplante de Médula Ósea del Hospital Universitari i Politécnic La Fe de Valéncia, así como Catedrático de Medicina de la Universitat de València. Presidente del Grupo PETHEMA, dirige el grupo de trabajo de Leucemia Mieloide Aguda.
CHARLAS
10:00 H. “ ESTUDIOS GENÉTICOS EN LA LMC : Utilidad en el Diagnóstico y en el Control de la Enfermedad”
Dra. Eva Barragán González.- Licenciada en Biología, Doctora por la Universidad de València (Premio Extraordinario del Doctorado), Facultativo Especialista e Bioquímica Clínica en la Unidad de Biología Molecular del Servicio de Análisis Clínicos del HUyP La Fe de València, Miembro del grupo de Investigación en Hematología del IIS La Fe. Vicepresidenta del Grupo de Biología Molecular en Hematología de la SEHH, Miembro de la Comisión Técnica del Programa de Cribado Neonatal de Enfermedades Congénitas en la Comunitat Valenciana de la Red Valenciana.
10: 15 H. “ TESTIMONIO – AELEMIC ESPAÑA. La vida no acaba con un diagnóstico”
Mateo Miras Hernández.- Paciente de LMC desde 2011, Técnico mantenimiento Quirófanos y Salas de Intervención Hospital Santa Lucía de Cartagena, estudiante de Medicina en la Universidad de Murcia UMU, Presidente de la Asociación Española Enfermos de Leucemia Mieloide Crónica. AELEMIC.
10:30 H “ LA ACTUALIDAD DEL PACIENTE DE LMC ”
Dra. Elvira Mora Casterá.- Médico Adjunto Hematología servicio de Hematología Hospital Universitari y Politècnic La Fe València. Pertenece al Grupo Español de Neoplasias Mieloproliferativas Filadelfia Negativas (GENFIN) y al grupo Español de LMC. Ha participado y participa en Estudios de Investigación ( Ensayos Clínicos) en el ámbito de diversas enfermedades hematológicas, especialmente LMC y otras Neoplasias Mieloproliferativas. Desde el Hospital La Fe, como investigadora principal o sub- investigadora.
11:00 H. 11:15 H. 11:20 H.
“ Turno de Preguntas para pacientes y asistentes a la jornada” “ Despedida y cierre de la Jornada “
En sala anexa del Hospital Universitari y Politècnic de La Fe València.
28
Más información
4th INTERNATIONAL WORKSHOP ON THE BIOLOGY, PREVENTION AND TREATMENT OF RELAPSE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
4th International Workshop on Biology, Prevention and Treatment of Relapse after Hematopoietic Stem Cell Transplantation www.relapse-after-hsct.com
REGISTER TODAY September 21-22, 2018
Intercontinental Chicago magnificent mile, chicago, il
TOPICS Epidemiology of relapse Biology of relapse
• Microenvironment
• Checkpoint blockade
• HLA-loss
• T-cell impairment
• NK/CIK cells
• Intrinsic tumor resistance
Methods to prevent and treat relapse
• Tumor-specific T-cells
• Checkpoint inhibitors
• Genetically modified T-cells • CAR T-cells
• NK/CIK cells
• Vaccination
• Antibodies (e.g., bispecific and
polyclonal)
• Hypomethylating agents • HDAC inhibitors
• I(mImmiDuns)modulating drugs
• Small molecular and TKIs
Role of minimal residual disease
• FACS
• Next Generation Sequencing • Digital PCR
Clinical results and trials
• Lymphoid Malignancies • Acute Leukemias
• Multiple Myeloma
• MDS and MPN
Lugar: Intercontinental Magnificent Mile (Chicago, IL, USA)
Fecha: 21 y 22 de septiembre de 2018
Organiza: American Society for Blood and Marrow Transplantation
(ASBMT)
Coordinan: Nicolaus Kröger, Alan Wayne, Sergio Giralt y Michael Bishop
MThe iUcnivherasitey olf CBhiciasgohMoedpicine/USA
Register today for the 4th International Workshop on Biology, Prevention and Treatment of Relapse after HSCT. Relapse and disease progression are the leading causes of treatment failure for most hematologic malignancies treated with both allogeneic and autologous hematopoietic stem cell transplantation (HSCT). The planned objectives of the workshop are designed to present the latest scientific and clinical advances related to relapse after HSCT and to provide a forum for the presentation of ongoing laboratory, translational, and clinical research specifically related to this field. The educational content of this conference is relevant for medical and pediatric hematologists- oncologists, hematopoietic stem and immune cell translational and basic scientists, hematopathologists, physicians-in-training (Fellows/Residents/ Post Docs), advance practice providers, pharmacists, oncology nurses and other associated allied health professionals. The workshop will feature internationally recognized speakers from a multidisciplinary, diverse group comprised of basic and translational scientists and clinical investigators.
The Organizing Committee has been working hard to make the Fourth International Workshop a truly valuable experience for all participants. We look forward to welcoming you to the beautiful city of Chicago.
SMeemorrgialiSoloaGn Kierttearilntg Cancer Center/USA
NUniviecrsoitylHaouspistal KHamrböurg/eDEr
AChildaren‘s HWospaitayl LnoseAngeles/
USC Norris Comprehensive Cancer Center/USA
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Chicago Pritzker School of Medicine and the Organizing Committee. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 14 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
The American Medical Association (AMA) has an agreement of mutual recognition of continuing medical education (CME) credit with the European Union of Medical Specialties (UEMS).
International physicians interested in converting AMA PRA Category 1 CreditTM to EACCME credit should contact the UEMS.
agenda
